drugset / Trial / NCT02370693
Comparing and Combining Bortezomib and Mycophenolate in SSc Pulmonary Fibrosis
Phase 2
Completed
9 enrolled
Northwestern University
National Heart, Lung, and Blood Institute (NHLBI) · collab
RandomizedParallel-groupTriple-blindTreatment
Summary
The purpose of this study is to look at whether bortezomib, mycophenolate or the combination of both is better to treat scarring of the lung caused by Systemic Sclerosis.
Timeline
- Start
- 2016-03
- Primary completion
- 2019-12-16
- Completion
- 2020-01-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Bortezomib | Small molecule | 1.3 mg/m2 | Subcutaneous |
| Comparator | Mycophenolate Mofetil | Small molecule | 1.5 g | Oral |